本研究通过前瞻性试验的事后分析，首次证实基于诊断活检组织的Decipher基因组分类器（GC）评分（≥0.45）可独立预测前列腺癌（PCa）局灶治疗失败风险（6个月失败率46% v 21%，OR 2.61；18个月76% v 44%，OR 3.58），为个体化治疗选择提供了关键分子标志物。 能够预测 ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting the Decipher ® Prostate Biopsy genomic classifier (GC) may help guide treatment ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...

025年8月27日，北京大学/昌平实验室高歌课题组于Nature Communication发表研究论文，提出了空间组学建模的解耦建模的新方法 ...

Comparative effectiveness of a patient-centered prostate biopsy report in clinical prostate cancer practice. This is an ASCO Meeting Abstract from the 2018 Genitourinary Cancers Symposium. This ...

Can Genomic Data Guide the Postoperative Management of Prostate Cancer? Finally, observing the primary end point of metastasis may have been subject to ascertainment bias. 14 Specifically, whereas ...

Veracyte (NASDAQ:VCYT) and Decipher Biosciences (DECI), commercial-stage precision oncology company focused on urologic cancers, inked a definitive acquisition agreement under which former will ...

Bunzz, a Singapore-based web3×LLM tech web3-startup, is thrilled to announce the successful release of “DeCipher“, a revolutionary AI-powered tool designed to transform the process of generating Smart ...